PREP

Opioid agonist therapy (OAT) must be widely disseminated and increased in Ukraine in order to optimize HIV prevention and treatment goals, according to a recent study published in The Lancet.

Antiretroviral therapy may not be entirely effective in restoring the immune protection resulting from viral infections or childhood vaccines received prior to becoming HIV-positive.
 

The findings support the inclusion of these patient populations in ICI-based clinical trials and treatment.

Hospitalization offers unique opportunities to engage out-of-care individuals with the ultimate goal of improving their HIV outcomes and reducing health disparities.

The app takes the authoritative, evidence-based 2015 World Health Organization pre-exposure prophylaxis guidelines and adapts for a mobile device.
 

Top news of the day from across the health care landscape.

The loss of immunity, also referred to as “HIV-associated immune amnesia,” could be related to why people with HIV who are on ART still have shorter lives on average than people without HIV, the study noted.  

Dosing based around the frequency of sexual activity provides adequate protection for men vulnerable to HIV infection.

Study shows a high burden of sexually transmitted infections among both individuals starting and persistently using PrEP.

Among eligible MSM, PrEP use is associated with lower levels of HIV anxiety, a mental health benefit that could be incorporated into initiatives that aim to increase uptake. 

Through the Ready, Set, PrEP program, qualified patients from across the United States can access PrEP medication for the prevention of HIV, for free.

Program allows women in sub-Saharan Africa who visited any of 16 different maternal-child health centers to receive a behavioral assessment designed to provide information about HIV risk, learn about PrEP, and obtain a prescription for PrEP, if desired.